Target
Retinoic acid receptor RXR-alpha
Ligand
BDBM50346091
Substrate
n/a
Meas. Tech.
in vitro transactivation assay
EC50
5000±n/a nM
Citation
 Vassilatis, DKSpathis, ADFokas, D Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease US Patent  US10946019 Publication Date 3/16/2021 
Target
Name:
Retinoic acid receptor RXR-alpha
Synonyms:
NR2B1 | Nuclear receptor subfamily 2 group B member 1 | Nuclear receptor subfamily 4 group A member 2 | Nuclear receptor subfamily 4 group A member 2/Retinoic acid receptor RXR-alpha | RXRA | RXRA_HUMAN | Retinoic acid receptor RXR-alpha/gamma | Retinoid X receptor alpha | Retinoid receptor
Type:
PROTEIN
Mol. Mass.:
50820.38
Organism:
Homo sapiens (Human)
Description:
ChEMBL_1456363
Residue:
462
Sequence:
MDTKHFLPLDFSTQVNSSLTSPTGRGSMAAPSLHPSLGPGIGSPGQLHSPISTLSSPINGMGPPFSVISSPMGPHSMSVPTTPTLGFSTGSPQLSSPMNPVSSSEDIKPPLGLNGVLKVPAHPSGNMASFTKHICAICGDRSSGKHYGVYSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYCRYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSANEDMPVERILEAELAVEPKTETYVEANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSELPLDDQVILLRAGWNELLIASFSHRSIAVKDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDMQMDKTELGCLRAIVLFNPDSKGLSNPAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT
  
Inhibitor
Name:
BDBM50346091
Synonyms:
4-(5-ethyl-6-methyl-2-phenylpyrimidin-4-ylamino)benzoic acid | CHEMBL1784109 | US10946019, Example 13
Type:
Small organic molecule
Emp. Form.:
C20H19N3O2
Mol. Mass.:
333.3838
SMILES:
CCc1c(C)nc(nc1Nc1ccc(cc1)C(O)=O)-c1ccccc1
Structure:
Search PDB for entries with ligand similarity: